Company intelligence / Profile preview

AusCann Group Holdings

Sydney, New South Wales, Australia

Ownership: Private
Employees: ~27
Development stage: Other

Overview

AusCann has launched THC/CBD powder-based hard-shell capsules using the Neuvis platform for pain and related indications. Products include veterinary medicines CPAT-01 for pain/inflammation in dogs and DermaCann for skin/immune function in dogs.

Therapeutic areas: ImmunologyNeurologyDermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Canopy Growth (past collaboration)

Beyond the preview

Go deeper on AusCann Group Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AusCann Group Holdings.

Explore the full profile